Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

521278

registered interest
date	24/05/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Heart Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to the Answer of 12 May 2016 to Question 36856, on heart diseases, when his Department plans to instruct NICE to develop specific clinical guidelines on the diagnosis, referral and treatment of patients with heart valve disease.
tabling member constituency	Scunthorpe
tabling member printed	Nic Dakin
uin	38151
answer	answer is ministerial correction date of answer 06/06/2016 answer text <p>NHS England is responsible for commissioning clinical guidelines on healthcare topics from the National Institute for Health and Care Excellence (NICE).</p><p> </p><p>NHS England has advised that it has no plans to ask NICE to develop specific clinical guidelines on the diagnosis, referral and treatment of patients with heart valve disease at this time.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 06/06/2016 13:50:12 answering member 4020 label Biography information for George Freeman
tabling member	4056 label Biography information for Nic Dakin

520818

registered interest
date	23/05/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Health Services: Procurement
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps he is taking to ensure that (a) science-related contracts and (b) outsourced activities in the health sector are awarded to organisations that demonstrate a commitment to high professional standards and invest in the professional development of their scientific workforce.
tabling member constituency	Scunthorpe
tabling member printed	Nic Dakin
uin	37785
answer	answer is ministerial correction date of answer 26/05/2016 answer text <p>All procurement processes must identify key objectives, performance indicators and critical success factors and ensure these are reflected in the tender documents against which organisations are invited to bid. Where appropriate, specific ongoing training and development needs can be included as specific terms in the final signed contract.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 26/05/2016 14:10:42 answering member 4020 label Biography information for George Freeman
tabling member	4056 label Biography information for Nic Dakin

519186

registered interest
date	18/05/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Science
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what his policy is on ensuring that all science-related government contracts and outsourced activities are awarded to organisations that demonstrate a commitment to high professional standards and invest in the professional development of their scientific workforce; and if he will make a statement.
tabling member constituency	Scunthorpe
tabling member printed	Nic Dakin
uin	37123
answer	answer is ministerial correction date of answer 23/05/2016 answer text <p>All procurement processes must identify key objectives, performance indicators and critical success factors and ensure these are reflected in the tender documents against which organisations are invited to bid. Where appropriate, specific ongoing training and development needs can be included as specific terms in the final signed contract.</p><p> </p><p>The Department awards research contracts through the National Institute for Health Research (NIHR). Contractual conditions require that the research is carried out by appropriately experienced, qualified and trained personnel with all due skill, care and diligence.</p><p> </p><p>The NIHR Faculty includes all of the people funded through NIHR contracts who work in the national health service, universities and registered charities in England. The NIHR Faculty offers career pathways in research and provides training and development opportunities.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 23/05/2016 14:25:12 answering member 4020 label Biography information for George Freeman
tabling member	4056 label Biography information for Nic Dakin

448350

registered interest
date	27/01/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps his Department is taking to ensure that the recommendations from the Accelerated Access Review interim report and the Cancer Drugs Fund consultation are not contradictory.
tabling member constituency	Scunthorpe
tabling member printed	Nic Dakin
uin	24506
answer	answer is ministerial correction date of answer 04/02/2016 answer text <p>The Accelerated Access Review's independent chair, Sir Hugh Taylor, is considering a range of options for accelerating patient access to innovative products, as set out in the interim report. The review team is working closely with NHS England to ensure that the review recommendations are aligned with emerging thinking on the Cancer Drugs Fund.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 04/02/2016 11:03:55 answering member 4020 label Biography information for George Freeman
tabling member	4056 label Biography information for Nic Dakin

447245

registered interest
date	25/01/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	National Clinical Directors
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many National Clinical Directors will be appointed; and what areas those National Clinical Directors will cover after April 2016.
tabling member constituency	Scunthorpe
tabling member printed	Nic Dakin
uin	23872
answer	answer is ministerial correction date of answer 01/02/2016 answer text <p>NHS England will be supported by 17 National Clinical Directors (NCDs) from 1 April 2016. 14 of these roles have been advertised and will be newly appointed. Three NCDs will continue in post into 2016/17; these are NCDs for Maternity and Women’s Health, Learning Disabilities and Innovation. The 17 roles are:</p><p> </p><p>National Clinical Director (Major Programmes):</p><p>— Cancer</p><p>— Mental Health</p><p>— Diabetes and Obesity</p><p>— Learning Disabilities</p><p>— Urgent and Emergency Care</p><p>— Maternity and Women’s Health</p><p>— Innovation</p><p> </p><p>National Clinical Director (Service Improvement):</p><p>― Cardiac Services</p><p>― Stroke</p><p>― Respiratory</p><p>― End of Life Care</p><p>― Diagnostics, including Imaging and Endoscopy</p><p>― Musculoskeletal</p><p>― Dementia</p><p>― Emergency Preparedness and Critical Care</p><p> </p><p>National Clinical Director (Population Groups):</p><p>— Children, Young People and Transition to Adulthood</p><p>— Older People and Integrated Person-Centred Care</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 01/02/2016 13:50:28 answering member 4020 label Biography information for George Freeman
tabling member	4056 label Biography information for Nic Dakin

447403

registered interest
date	25/01/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	National Clinical Directors
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how the objectives for NHS England's National Clinical Directors post April 2016 will be agreed.
tabling member constituency	Scunthorpe
tabling member printed	Nic Dakin
uin	23929
answer	answer is ministerial correction date of answer 28/01/2016 answer text <p>From 1 April 2016, objectives for the National Clinical Directors will be set according to the priority areas and major programmes, as set out in the Mandate and planning guidance. They will relate, where appropriate, to established programmes of service improvement.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 28/01/2016 15:43:48 answering member 4020 label Biography information for George Freeman
tabling member	4056 label Biography information for Nic Dakin

447406

registered interest
date	25/01/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what plans his Department has to hold NHS bodies accountable to the recommendations of the Accelerated Access Review.
tabling member constituency	Scunthorpe
tabling member printed	Nic Dakin
uin	23928
answer	answer is ministerial correction date of answer 28/01/2016 answer text <p>The Accelerated Access Review, which was set up to look at speeding up access to innovative drugs including those for rare diseases, devices and diagnostics for National Health Service patients, has been making strong progress since it was first announced in November 2014.</p><p><br> The review is independently chaired by Sir Hugh Taylor and has been engaging stakeholders extensively since the summer to gather evidence on the big questions the review is considering, and has developed a number of emerging solutions.</p><p><br> Sir Hugh published his interim report of the review on 27 October 2015. The report is high-level, direction-setting and grounded in evidence gathered through the review’s stakeholder engagement to date. Included in the report were proposals for a National Innovation Partnership of key bodies in the innovation pathway who would be party to a Concordat committing them to the ambitions set out in the review. The review has used a second phase of engagement to work closely with industry stakeholders, Government, the NHS and arm’s length bodies on these and other proposals set out in the interim report.</p><p><br> In April 2016 the review will conclude with Sir Hugh making his final recommendations to Government. The Department will review these recommendations and consider how best to respond.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 28/01/2016 15:39:38 answering member 4020 label Biography information for George Freeman
tabling member	4056 label Biography information for Nic Dakin

428414

registered interest
date	16/11/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Leukaemia: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the availability of medicines which treat patients with chronic myeloid leukaemia who are resistant or intolerant to tyrosine kinase inhibitor therapies.
tabling member constituency	Scunthorpe
tabling member printed	Nic Dakin
uin	16337
answer	answer is ministerial correction date of answer 19/11/2015 answer text <p>The National Institute for Health and Care Excellence (NICE) has issued technology appraisal guidance on a number of tyrosine kinase inhibitor therapies as possible treatment options for patients with chronic myeloid leukaemia.</p><br /><p>NICE has recommended imatinib (Gleevec) and nilotinib (Tasigna) as first-line treatments for some patients with chronic myeloid leukaemia and nilotinib for some patients who are intolerant or resistant to imatinib. NICE has not been able to recommend dasatinib (Sprycel) and bosutinib (Bosulif) for use on the National Health Service. Further information about NICE’s guidance on chronic myeloid leukaemia is available at:</p><p /> <p><a href="http://%20%0d%0dwww.nice.org.uk/guidance/conditions-and-diseases/cancer/blood-and-bone-marrow-cancers" target="_blank">www.nice.org.uk/guidance/conditions-and-diseases/cancer/blood-and-bone-marrow-cancers</a></p><p><strong></strong></p><p>Commissioners are legally required to fund drugs and treatments recommended in NICE technology appraisal guidance within three months of its final guidance being issued. In the absence of guidance from NICE, it is for commissioners to make decisions on whether to fund medicines based on an assessment of the available evidence.</p><br /><p>Dasatinib and bosutinib are available as second-line treatment options for some patients with chronic myeloid leukaemia through the Cancer Drugs Fund (CDF). A further drug, ponatinib, is available through the CDF as a possible first-line treatment option for some patients with chronic myeloid leukaemia.</p><p><strong></strong></p><br /> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 19/11/2015 17:24:43 answering member 4020 label Biography information for George Freeman
tabling member	4056 label Biography information for Nic Dakin

427745

registered interest
date	10/11/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, when he expects NHS England to publish the first and second quarter figures for Cancer Drugs Fund notifications and individual Cancer Drugs Fund requests for 2015-16; and if he will make a statement.
tabling member constituency	Scunthorpe
tabling member printed	Nic Dakin
uin	15850
answer	answer is ministerial correction date of answer 17/11/2015 answer text <br /><p>The information for the first quarter of 2015-16 was published on NHS England’s website on 10 November 2015 and is available at:</p><br /><p><a href="http://www.england.nhs.uk/ourwork/pe/cdf/" target="_blank">www.england.nhs.uk/ourwork/pe/cdf/</a></p><br /><p>Information for the second quarter is currently being finalised and NHS England expects to publish this in the near future.</p><p><strong></strong></p><p><strong></strong></p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 17/11/2015 16:36:03 answering member 4020 label Biography information for George Freeman
tabling member	4056 label Biography information for Nic Dakin

427747

registered interest
date	10/11/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, pursuant to the Answer of 16 September 2015 to Question 10091, what the implications for his policies are of the decision by NHS England to remove (a) the pancreatic cancer drug Abraxane and (b) 22 other drugs and indications from the Cancer Drugs Fund List.
tabling member constituency	Scunthorpe
tabling member printed	Nic Dakin
uin	15851
answer	answer is ministerial correction date of answer 17/11/2015 answer text <p>We remain committed to continuing to invest in the Cancer Drugs Fund (CDF).</p><br /><p>NHS England is responsible for the operational management of the Fund. Following appeals and further discussions with pharmaceutical companies, 18 drug and indication combinations, including Abraxane for pancreatic cancer, were removed from the national CDF list on 4 November 2015.</p><p><strong></strong></p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 17/11/2015 16:38:08 answering member 4020 label Biography information for George Freeman
tabling member	4056 label Biography information for Nic Dakin